Ambrilia Biopharma Inc.

Ambrilia Biopharma Inc.

August 05, 2008 09:06 ET

Ambrilia to Present at Canaccord Adams 28th Annual Global Growth Conference

MONTREAL, QUEBEC--(Marketwire - Aug. 5, 2008) - Ambrilia Biopharma Inc. (TSX:AMB) today announced that Dr. Philippe Calais, President and CEO, will present the Company and its projects at the Canaccord Adams 28th Annual Global Growth Conference to be held in Boston, August 12-14. This presentation will take place on Thursday, August 14, at 8:00 am local time.

A live webcast of the presentation will be available on the Company's website at Investors' section, Webcasts and Conference Calls. A webcast replay will be available approximately 1 hour after the end of the presentation and will be accessible for 90 days.


Ambrilia Biopharma Inc. (TSX:AMB) is a biotechnology company focused on the discovery and development of novel treatments for viral diseases and cancer. The Company's strategy aims to capitalize on its broad portfolio and original expertise in virology. Ambrilia's product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a therapeutic peptide for prostate cancer, a targeted delivery technology for cancer, an HIV protease inhibitor program (exclusive worldwide rights granted to Merck & Co., Inc.) as well as HIV integrase and entry inhibitors, Hepatitis C inhibitors and anti-Influenza A compounds. Ambrilia's head office, research and development and manufacturing facilities are located in Montreal with a regional office in France.

Contact Information